<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180477</url>
  </required_header>
  <id_info>
    <org_study_id>107.251</org_study_id>
    <nct_id>NCT02180477</nct_id>
  </id_info>
  <brief_title>Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers</brief_title>
  <official_title>Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the relative bioavailability of UHAC 62 XX capsule and two different
      tablet formulations (TF1 and TF2), and to obtain data for rational design of a subsequent
      pivotal bioequivalence (BE) study between capsule and tablet formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed concentration in plasma)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-72hr (Area under the concentration-time curve in plasma from zero time to 72 hours)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (Time to reach maximum concentration)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Terminal half-life in plasma)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (Area under the concentration-time curve in plasma from zero time to infinity)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT 0-t (Mean residence time in the body from zero time to the time of the last quantifiable drug concentration)</measure>
    <time_frame>up to 72 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 14 days after last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>UHAC 62 XX TF1 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UHAC 62 XX TF2 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UHAC 62 XX capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHAC 62 XX - TF1 tablet</intervention_name>
    <arm_group_label>UHAC 62 XX TF1 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX TF2 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHAC 62 XX - TF2 tablet</intervention_name>
    <arm_group_label>UHAC 62 XX TF1 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX TF2 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHAC 62 XX - capsules</intervention_name>
    <arm_group_label>UHAC 62 XX TF1 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX TF2 tablet</arm_group_label>
    <arm_group_label>UHAC 62 XX capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 20 and &lt;= 35 years

          -  Weight: BMI &gt;= 18.5 and &lt; 25 (Weight (kg) / Height (mÂ²)

          -  Subjects who are judged by the investigator to be appropriate as the subjects of the
             study based on results of screening test

          -  Subjects who volunteer to participate and are able to fully understand and agree with
             this study by written informed consent

        Exclusion Criteria:

          -  History of gastrointestinal ulcer or surgery of gastrointestinal tract (except
             appendectomy)

          -  History of hypersensitivity to meloxicam and/or salicylate (aspirin) and/or
             Non-steroidal anti-inflammatory drugs (NSAIDs)

          -  History of aspirin induced asthma (bronchial asthma induced by NSAIDs)

          -  History of alcohol or drug abuse

          -  Participation to another trial with an investigational drug within 4 months prior to
             the administration

          -  Whole blood donation more than 400 ml within 3 months prior to the administration

          -  Whole blood donation more than 100 ml within 1 month prior to the administration

          -  Donation of constituent of blood of more than 400 ml within 1 month prior to the
             administration

          -  Any medication within 10 days prior to the administration

          -  Excessive physical activities within 7 days prior to the administration

          -  Alcohol drinking within 3 days prior to the administration

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Other than above, those who are judged by the investigator to be inappropriate as the
             subjects of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

